Core Viewpoint - Jianfa Zhixin, a subsidiary of Xiamen Jianfa Group, is set to be listed on the Shenzhen Stock Exchange on September 25, 2025, focusing on high-value medical device distribution and supply chain services in China [1] Group 1: Company Overview - Jianfa Zhixin was established on August 30, 2010, and is headquartered in Shanghai [1] - The company operates in the medical device direct sales and distribution sector, providing centralized operation services for medical consumables to hospitals [1] Group 2: Financial Performance - For Q3 2025, Jianfa Zhixin reported revenue of 14.861 billion yuan, ranking 12th in the industry, while the industry leader, Shanghai Pharmaceuticals, reported revenue of 215.072 billion yuan [2] - The net profit for the same period was 284 million yuan, placing the company 11th in the industry, with the top performer, Shanghai Pharmaceuticals, achieving a net profit of 5.986 billion yuan [2] Group 3: Financial Ratios - As of Q3 2025, Jianfa Zhixin's debt-to-asset ratio was 83.52%, exceeding the industry average of 59.74% [3] - The company's gross profit margin was 7.98%, which is below the industry average of 13.11% [3] Group 4: Management and Shareholder Information - The chairman, Yu Feng, has a salary of 1.8949 million yuan for 2024, while the general manager, Wu Shengyong, has a salary of 2.7466 million yuan [4] - The controlling shareholder is Xiamen Jianfa Medical Health Investment Co., Ltd., with actual control by the Xiamen Municipal Government's State-owned Assets Supervision and Administration Commission [4] Group 5: Shareholder Dynamics - As of September 30, 2025, the number of A-share shareholders increased by 151.60% to 38,000, while the average number of circulating A-shares held per shareholder decreased by 60.25% to 1,327.4 [5] - The company is recognized for its strong backing from the Xiamen State-owned Assets Supervision and Administration Commission and its integration of information management with traditional medical device distribution [5]

证券日报网讯10月30日晚间，建发致新（301584）发布公告称，公司无逾期担保的情形，不涉及诉讼的 担保金额情形及因担保被判决败诉而应承担的损失金额等。 ...

Core Insights - The stock of Jianfa Zhixin increased by 2.35% today, with a turnover rate of 38.54% and a trading volume of 687 million yuan, showing a fluctuation of 9.96% [2] - Institutional investors net sold 22.48 million yuan, while brokerage seats collectively net bought 8.28 million yuan [2] - The stock has appeared on the "Dragon and Tiger List" nine times in the past six months, with an average price drop of 0.15% the day after being listed and an average increase of 3.85% over the following five days [3] Trading Activity - The top five brokerage seats on the "Dragon and Tiger List" had a total transaction amount of 159 million yuan, with buying transactions amounting to 72.62 million yuan and selling transactions amounting to 86.82 million yuan, resulting in a net sell of 14.20 million yuan [2] - Among the brokerage seats listed, four were institutional special seats, with total buying amounts of 55.02 million yuan and selling amounts of 77.50 million yuan, leading to a net sell of 22.48 million yuan [2] Fund Flow - Today's main capital flow into the stock was 7.95 million yuan, with large orders contributing a net inflow of 0.33 million yuan and big orders contributing a net inflow of 7.62 million yuan [3] - Over the past five days, the main capital has seen a net outflow of 146 million yuan [3]

证券代码：301584 证券简称：建发致新 公告编号：2025-012 上海建发致新医疗科技集团股份有限公司 关于公司2025年度对外担保额度预计的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别风险提示： 上海建发致新医疗科技集团股份有限公司（以下简称"公司"）及控股子公 司提供担保总额超过公司最近一期经审计净资产100%，对资产负债率超过70%的控 股子公司预计担保金额超过公司最近一期经审计净资产50%，提请投资者充分关注 担保风险。 本次预计的对外担保事项，系合并报表范围内公司及子公司之间的担保，上 述担保事项已经公司第三届董事会第八次会议、第三届监事会第七次会议和2024 年年度股东大会审议通过。 一、对外担保情况概述 根据公司经营发展战略、资金预算和资金安全等需要，自公司2024年年度股 东大会之日起，至2025年年度股东大会召开之日止，公司及控股子公司拟向各银 行等金融机构申请综合授信总额不超过人民币150亿元（其中40亿元尚待公司2025 年第二次临时股东大会审议通过后生效）。 鉴于上述授信总额中部分授信额度的融资主体为公司控股子公司， ...

Market Overview - As of October 29, the Shanghai Composite Index closed at 4016.33 points, up 28.11 points, with a gain of 0.70% [1] - The Shenzhen Component Index closed at 13691.38 points, up 261.28 points, with a gain of 1.95% [1] - The ChiNext Index closed at 3324.27 points, up 94.70 points, with a gain of 2.93% [1] High Turnover Stocks - A total of 84 A-shares had a turnover rate exceeding 20% on this day [1] - Notable stocks with high turnover rates include: - 泰凯英 (Tykang Technology) with a turnover rate of 69.82% and a closing price of 22.29 CNY, up 3.00% [1] - C超颖 (C Chaoying) with a turnover rate of 64.48% and a closing price of 86.75 CNY, up 12.08% [1] - 北方长龙 (Beifang Changlong) with a turnover rate of 51.81% and a closing price of 162.58 CNY, down 3.40% [1] - C禾元-U (C Heyuan) with a turnover rate of 50.96% and a closing price of 113.22 CNY, up 24.28% [1] Additional High Turnover Stocks - Other notable stocks with significant turnover rates include: - C必贝特-U (C Bibete) with a turnover rate of 49.99% and a closing price of 31.86 CNY, up 2.74% [1] - 威士顿 (Winston) with a turnover rate of 48.37% and a closing price of 61.52 CNY, up 19.99% [1] - 云汉芯城 (Yunhan Xincheng) with a turnover rate of 47.58% and a closing price of 236.20 CNY, up 6.16% [1] - 海峡创新 (Haixia Innovation) with a turnover rate of 45.41% and a closing price of 9.28 CNY, up 0.98% [1]

Core Points - The stock of Jianfa Zhixin experienced a decline of 11.66% today, with a turnover rate of 48.21% and a trading volume of 886 million yuan, indicating significant market activity [2] - Institutional investors net sold 40.27 million yuan, while brokerage seats collectively net sold 4.08 million yuan [2] - The stock has been listed on the Dragon and Tiger list 8 times in the past six months, with an average price drop of 0.06% the day after being listed and an average increase of 3.73% over the following five days [3] Trading Activity - The top five trading departments accounted for a total transaction amount of 148 million yuan, with a buying amount of 51.61 million yuan and a selling amount of 95.97 million yuan, resulting in a net sell of 44.36 million yuan [2] - Among the trading departments listed today, four institutional specialized seats were involved, with total buying amounts of 42.15 million yuan and selling amounts of 82.42 million yuan, leading to a net sell of 40.27 million yuan [2] Fund Flow - The stock saw a net outflow of 46.41 million yuan in main funds today, with a significant outflow of 18.12 million yuan from large orders and 28.29 million yuan from major funds [3] - Over the past five days, the main funds have seen a net inflow of 2.47 million yuan [3]

Group 1 - The core viewpoint of the article highlights the financial performance of Jianfa Zhixin for the third quarter of 2023, showing significant growth in revenue and net profit [1] - For the first three quarters of 2025, the company reported revenue of approximately 14.861 billion yuan, an increase of 10.18% year-on-year [1] - The net profit attributable to shareholders was about 230 million yuan, reflecting a year-on-year increase of 45.01% [1] - The basic earnings per share reached 0.64 yuan, which is a 45.45% increase compared to the previous year [1] Group 2 - As of the report date, Jianfa Zhixin's market capitalization stands at 16.6 billion yuan [2]

Group 1 - The core point of the article is that Jianfa Zhixin announced the results of its board meeting and provided details on its revenue composition for the first half of 2025, highlighting its market position and financial performance [1] Group 2 - Jianfa Zhixin's third board meeting was held on October 24, 2025, in Xiamen, where various proposals, including the revision of company policies, were discussed [1] - For the first half of 2025, the revenue composition of Jianfa Zhixin was as follows: vascular interventional devices accounted for 54.88%, surgical instruments for 18.91%, in vitro diagnostic reagents (IVD) for 14.36%, medical equipment for 5.77%, and other medical devices for 4.69% [1] - As of the report date, Jianfa Zhixin's market capitalization was 16.6 billion yuan [1]

证券代码：301584 证券简称：建发致新 公告编号：2025-005 上海建发致新医疗科技集团股份有限公司 关于召开2025年第二次临时股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东会届次：2025年第二次临时股东大会 2、股东会的召集人：董事会 经上海建发致新医疗科技集团股份有限公司（以下简称"公司"）第三届董事 会第十次会议审议通过，决定召开公司2025年第二次临时股东大会。 3、会议召开的合法、合规性：本次会议的召集、召开符合《中华人民共和国 公司法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自 律监管指引第2号—创业板上市公司规范运作》等法律、行政法规、部门规章、规 范性文件及《公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2025年11月12日14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025年11月12日9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互 联网投票系统投票的具体时间为2025年 ...

证券代码：301584 证券简称：建发致新 公告编号：2025-004 二、监事会会议审议情况 1、审议通过《公司2025年第三季度报告》 上海建发致新医疗科技集团股份有限公司 关于第三届监事会第九次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 上海建发致新医疗科技集团股份有限公司（以下简称"公司"）第三届监事会 第九次会议通知于2025年10月13日以通讯方式送达，会议于2025年10月24日以通讯 方式召开。本次会议由李玉鹏先生主持，应出席监事3人，实际出席监事3人。本次 会议的通知、召开及审议程序符合有关法律法规和《公司章程》的规定，所作决议 合法有效。本次会议经逐项表决通过以下事项： 经审核，监事会认为董事会编制和审议《公司2025年第三季度报告》的程序符 合法律、行政法规及中国证监会的规定，报告内容真实、准确、完整地反映了公司 的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 具体内容详见公司于同日披露于指定信息披露媒体及巨潮资讯网的《公司2025 年第三季度报告》（公告编号：2025-006）。 表决 ...